Navigation Links
Defective immune system response to smallpox vaccine detailed in new study

c dermatitis (as well as samples taken from healthy volunteers without skin disease and from people with another skin condition called psoriasis) to further investigate how dysfunctions in the immune response of people with eczema set the stage for eczema vaccinatum. When exposed to vaccinia virus, the skin samples from healthy volunteers and from those with psoriasis reacted by producing more LL-37. As a result, the replication of the virus was controlled and eventually halted. In contrast, LL-37 production was minimal in skin samples from people with atopic dermatitis and vaccinia replication was poorly controlled. Next, the scientists exposed skin samples from people with atopic dermatitis to vaccinia, and then added LL-37. With the LL-37 supplement, the skin cells successfully controlled the viral replication.

Dr. Leung and his group then looked more closely at why vaccinia infection fails to induce LL-37 production in atopic dermatitis skin. Comparing immune responses of skin cells grown in the lab from healthy volunteers and from people with atopic dermatitis, the researchers found that the latter skin samples produced excessive amounts of IL-4 and IL-13. Adding IL-4 and IL-13 to skin cells from healthy volunteers prior to vaccinia exposure reduced levels of LL-37 production. Conversely, when the scientists applied IL-4- and IL-13-neutralizing antibodies to skin samples from people with atopic dermatitis, LL-37 production increased significantly.

Together, these findings suggest a rationale for new treatment approaches to eczema vaccinatum, notes Dr. Leung. One approach involves developing drugs to mimic the action of LL-37 or developing LL-37-containing creams that could be applied to the skin in order to boost its ability to contain vaccinia virus infection. Another approach could be to develop agents to neutralize IL-4 and IL-13. Although no such drugs are currently marketed, compounds that can neutralize IL-4 and IL-13 are under study as p
'"/>

Source:NIH/National Institute of Allergy and Infectious Diseases


Page: 1 2 3

Related biology news :

1. Defective Gene Linked to Two Inherited Immune Deficiencies
2. Fox Chase Cancer Center scientists identify immune-system mutation
3. Genetically modified natural killer immune cells attack, kill leukemia cells
4. Studies reveal methods viruses use to sidestep immune system
5. Jumping gene helps explain immune systems abilities
6. Scientists solve structure of key protein in innate immune response
7. Rats infected as newborns grew up vulnerable to memory problems during an immune challenge
8. NYU study reveals how brains immune system fights viral encephalitis
9. Chemists identify immune system mechanism for methamphetamine binges
10. Multi-purpose protein regulates new protein synthesis and immune cell development
11. Genetic defects give the immune system the green light to attack the pancreas
Post Your Comments:
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... Researchers from LSU Health Sciences Center New Orleans ... of Child Health and Human Development (NICHD), Harvard School ... Medical School, have found for the first time that ... a week prior to pregnancy appears to significantly elevate ...
... - The inaugural Global Conference on Systems & ... Washington, DC, focuses on the convergence of complex large-scale ... The goal of the conference ... targeted complex systems, examined by domain, each successive year. ...
... early bird registration rates and register online now for ... WHAT: IOF WCO-ECCEO10 is a joint ... European Society for Clinical and Economic Aspects of Osteoporosis ... the world are expected to attend. The exciting scientific ...
Cached Biology News:Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2
(Date:10/20/2014)... The report “Pharmacy Automation Systems ... and Labeling Systems, Table-top Counters) by End-user (Inpatient ... & Trends to 2019” analyzes and studies the ... America, Europe, Asia-Pacific, and the Rest of the ... 30 figures spread through 300 pages and in-depth ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)...  GenVec, Inc. (NASDAQ: GNVC ) today announced ... its board of directors effective on October 24, 2014.   Dr. ... as its chairman from June 2006 to November 2013.  During ... Governance and Audit Committees of the board.  ... dedicated service to GenVec, and its stockholders," said Wayne ...
(Date:10/20/2014)... Rochelle, Virginia (PRWEB) October 20, 2014 ... of NDA Partners LLC, announced today that Ellen ... and legal support for the pharmaceutical industry, has ... and manager of its legal services practice. ... reports and expert witness and testimony, to top ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... 2010 Shire plc (LSE: SHP,NASDAQ: SHPGY ) the global specialty biopharmaceutical company, announces,results for the three months to March 31, 2010 . ... ... $718 million ... Total revenues ...
... , April 29, 2010 According to ... by,MarketsandMarkets ( http://www.marketsandmarkets.com ), The global oncology,biomarker market is ... 2009 to $9.5,billion in 2014 at a ... Oncology,Biomarkers Market report analyzes the oncology biomarkers diagnostics and,discovery ...
... also known as hypertension, is a serious health risk factor ... the molecular basis of the disease remains poorly understood. ... ( www.genome.org ), scientists have sequenced the genome of ... variants that will help researchers to understand causes of the ...
Cached Biology Technology:Shire's Replenished Portfolio Drives Excellent Quarterly Performance 2Shire's Replenished Portfolio Drives Excellent Quarterly Performance 3Shire's Replenished Portfolio Drives Excellent Quarterly Performance 4Shire's Replenished Portfolio Drives Excellent Quarterly Performance 5Shire's Replenished Portfolio Drives Excellent Quarterly Performance 6Shire's Replenished Portfolio Drives Excellent Quarterly Performance 7Shire's Replenished Portfolio Drives Excellent Quarterly Performance 8Shire's Replenished Portfolio Drives Excellent Quarterly Performance 9Shire's Replenished Portfolio Drives Excellent Quarterly Performance 10Shire's Replenished Portfolio Drives Excellent Quarterly Performance 11Shire's Replenished Portfolio Drives Excellent Quarterly Performance 12Shire's Replenished Portfolio Drives Excellent Quarterly Performance 13Shire's Replenished Portfolio Drives Excellent Quarterly Performance 14Shire's Replenished Portfolio Drives Excellent Quarterly Performance 15Shire's Replenished Portfolio Drives Excellent Quarterly Performance 16Shire's Replenished Portfolio Drives Excellent Quarterly Performance 17Shire's Replenished Portfolio Drives Excellent Quarterly Performance 18Shire's Replenished Portfolio Drives Excellent Quarterly Performance 19Shire's Replenished Portfolio Drives Excellent Quarterly Performance 20Shire's Replenished Portfolio Drives Excellent Quarterly Performance 21Shire's Replenished Portfolio Drives Excellent Quarterly Performance 22Shire's Replenished Portfolio Drives Excellent Quarterly Performance 23Shire's Replenished Portfolio Drives Excellent Quarterly Performance 24Shire's Replenished Portfolio Drives Excellent Quarterly Performance 25Shire's Replenished Portfolio Drives Excellent Quarterly Performance 26Shire's Replenished Portfolio Drives Excellent Quarterly Performance 27Shire's Replenished Portfolio Drives Excellent Quarterly Performance 28Shire's Replenished Portfolio Drives Excellent Quarterly Performance 29Shire's Replenished Portfolio Drives Excellent Quarterly Performance 30Shire's Replenished Portfolio Drives Excellent Quarterly Performance 31Shire's Replenished Portfolio Drives Excellent Quarterly Performance 32Shire's Replenished Portfolio Drives Excellent Quarterly Performance 33MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 2MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 3MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 4
... The active ingredient in Molecular Probes. ... appears to act as a free ... emission. Our original SlowFade formulation (S-2828) ... rate of fluorescein to almost zero ...
... IRsolution software provides quick and easy ... functions with Windows-based control. The software ... and FDA 21 CFR Part 11 regulations, ... of measurement. IRsolutions versatility enables use ...
b6-2A12...
... reagents for immune complex disruption (ICD) of ... using a combination of low pH and ... transferred to microplate wells which are coated ... to HIV-1 p24. The immobilized monoclonal antibody ...
Biology Products: